| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rheumatology 2001; 40: 147-151
© 2001 British Society for Rheumatology
Are antineutrophil cytoplasmic antibodies a marker predictive of relapse in Wegener's granulomatosis? A prospective study
Service de Médecine Interne, Hôpital Avicenne, Université Paris-Nord, 125, rue de Stalingrad, 93009 Bobigny Cedex,
1 Service de Néphrologie et d’Anatomopathologie, Hôpital Necker, Université de Paris, Paris and
2 Service de Pneumologie, Hôpital Louis-Pradel, Université Claude-Bernard, Lyon, France
Objectives. To investigate the predictive value of testing for antineutrophil cytoplasmic antibodies (ANCA) in 55 patients with systemic Wegener's granulomatosis (WG) included in a randomized, prospective trial comparing corticosteroids and oral or pulse cyclophosphamide.
Methods. All 55 patients received corticosteroids. A cyclophosphamide pulse of 0.7 g/m2 was given at the time of diagnosis. After the first pulse, the patients were assigned at random to receive either pulse or oral cyclophosphamide (2 mg/kg/day), independently of ANCA results. ANCA were sought using an immunofluorescence assay and an attempt was made to correlate them with relapse of WG. ANCA were monitored throughout the study.
Results. At the time of diagnosis, ANCA were detected in 48 (87%) patients, with a cytoplasmic labelling pattern in 44 and a perinuclear pattern in four. ANCA follow-up was available for 50 patients. ANCA disappeared in 34 patients and persisted in nine. For 79% of the patients, the clinical course improved with the disappearance of ANCA and deteriorated with their persistence or increased titre. Among the patients who were initially ANCA-positive, 23 relapses occurred. Relapses were more frequent when ANCA remained positive or reappeared [13/19 ANCA-positive patients vs 3/29 ANCA-negative patients (P<0.01)]. Nine relapses (39%) occurred in patients with persistent ANCA, and ANCA reappearance preceded relapse in eight (35%). The mean time between inclusion and relapse did not differ between the patients who became ANCA-negative and those who were persistently ANCA-positive (14.6±13.2 vs 14.4±8.2 months). The mean time to ANCA disappearance was similar for the patients who relapsed and those who did not. Corticosteroids and pulse or oral cyclophosphamide did not significantly modify the time to ANCA disappearance. Throughout the study, seven patients were ANCA-negative.
Conclusion. Although ANCA positivity was associated with relapse, discordance between cytoplasmic ANCA and disease activity was not unusual. In the absence of clinical manifestations, ANCA titres alone can serve as a warning signal but not indicate whether to adjust or initiate treatment.
KEY WORDS: Antineutrophil cytoplasmic antibodies, Wegener's granulomatosis, Corticosteroids, Cyclophosphamide.
Correspondence to: L. Guillevin.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. D. Finkielman, P. A. Merkel, D. Schroeder, G. S. Hoffman, R. Spiera, E. W. St. Clair, J. C. Davis Jr., W. J. McCune, A. K. Lears, S. R. Ytterberg, et al. Antiproteinase 3 Antineutrophil Cytoplasmic Antibodies and Disease Activity in Wegener Granulomatosis Ann Intern Med, November 6, 2007; 147(9): 611 - 619. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Hogan, R. J. Falk, H. Chin, J. Cai, C. E. Jennette, J. C. Jennette, and P. H. Nachman Predictors of Relapse and Treatment Resistance in Antineutrophil Cytoplasmic Antibody-Associated Small-Vessel Vasculitis Ann Intern Med, November 1, 2005; 143(9): 621 - 631. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Segelmark, B. D. Phillips, S. L. Hogan, R. J. Falk, and J. C. Jennette Monitoring Proteinase 3 Antineutrophil Cytoplasmic Antibodies for Detection of Relapses in Small Vessel Vasculitis Clin. Vaccine Immunol., September 1, 2003; 10(5): 769 - 774. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R H J A Slart, P L Jager, L Poot, D A Piers, J-W Cohen Tervaert, and C A Stegeman Clinical value of gallium-67 scintigraphy in assessment of disease activity in Wegener's granulomatosis Ann Rheum Dis, July 1, 2003; 62(7): 659 - 662. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Stegeman Anti-neutrophil cytoplasmic antibody (ANCA) levels directed against proteinase-3 and myeloperoxidase are helpful in predicting disease relapse in ANCA-associated small-vessel vasculitis Nephrol. Dial. Transplant., December 1, 2002; 17(12): 2077 - 2080. [Full Text] [PDF]
|
|
|
|
|
|
F. J. van der Woude Taking anti-neutrophil cytoplasmic antibody (ANCA) testing beyond the limits Nephrol. Dial. Transplant., December 1, 2002; 17(12): 2081 - 2083. [Full Text] [PDF]
|
|